Stem Cell Retroviral Gene Therapy Trials May Proceed On Case-By-Case Basis
Executive Summary
The 27 hematopoietic stem cell trials in the U.S. that use retroviral vectors should be allowed to proceed on a case-by-case basis based on risk/benefit profiles, FDA's Biologics Response Modifiers Advisory Committee agreed at its Feb. 28 meeting